SCHEMBL6701738

SCHEMBL6701738

CN(C(=O)Cc1ccc(F)cc1)C1CCNCC1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 2/20 0.55
SLC6A4 P31645 4/20 0.49
SLC6A2 P23975 3/20 0.49
SLC6A3 Q01959 2/20 0.49
TACR1 P25103 2/20 0.47
CHRM1 P11229 1/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.47
POLB P06746 1/20 0.47
APEX1 P27695 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
KCNH2 Q12809 3/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
USP30 Q70CQ3 1/20 0.43
GPR119 Q8TDV5 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTR2A P28223 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5860907 0.83 CCR5 (0.56) CCR5CHRM1PTGDR2SMN1; SMN2
SCHEMBL4164384 0.83 MEN1 (0.56) CCR5SLC6A4SLC6A2SLC6A3TACR1
SCHEMBL3940288 0.82 TACR1 (0.64) SLC6A4SLC6A2SLC6A3TACR1KCNH2
SCHEMBL13543040 0.81 POLB (0.56) CCR5SLC6A4SLC6A2SLC6A3TACR1
SCHEMBL341156 0.79 TACR1 (0.58) SLC6A4SLC6A2SLC6A3TACR1POLB
SCHEMBL28646233 0.78 CCR5 (0.51) CCR5SLC6A4SLC6A2SLC6A3PTGDR2
SCHEMBL13543041 0.78 SMN1; SMN2 (0.57) CCR5SLC6A4SLC6A2SLC6A3TACR1
SCHEMBL27712266 0.77 TACR1 (0.58) SLC6A4SLC6A2SLC6A3TACR1KCNH2
SCHEMBL27613175 0.76 TACR1 (0.55) CCR5SLC6A4SLC6A2SLC6A3TACR1
SCHEMBL339704 0.76 TACR1 (0.55) SLC6A4SLC6A2SLC6A3TACR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040006081-A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2004-01-08 US disclosed
CN-1441781-A Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity ASTRAZENECA AG (SE) 2003-09-10 CN disclosed
EP-1289957-A1 PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca AB (SE) 2003-03-12 EP disclosed
WO-2001087839-A1 PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006081-A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity CCR5, CCR2, CCR1 CCR5 1/4885SLC6A4 1992/4885SLC6A2 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.